Investigating the psychometric properties of patient reported outcome measures in individuals with chronic diabetic neuropathic pain: prospective longitudinal cohort study protocol

Poonam Mehta1, Leica Sarah Claydon2, Ramakrishnan Mani1, Paul Hendrick3, David G. Baxter1

1Centre for Health, Activity, and Rehabilitation Research, University of Otago, Dunedin, New Zealand, 2Department of Allied Health and Medicine, Anglia Ruskin University, Chelmsford Campus, Essex, UK, 3Division of Physiotherapy Education, Nottingham City Hospital, Nottingham, UK

Background: The prevalence of diabetes in New Zealand is estimated to be 7% of the total population. And higher incidence rates of peripheral neuropathic pain (NeP) in diabetic populations have been estimated (between 3 and 25%). A range of outcome measures (OMs) are used to evaluate a change following an intervention, in diabetic NeP clinical trials, but very few have adequate psychometric properties (PMPs) for key dimensions. This study aims to investigate the remaining PMPs (which have not been investigated so far) of established specific pain intensity and physical functional OMs in adults (>18 years) with chronic diabetic NeP.

Methods and analysis: This prospective longitudinal cohort study aims to recruit a total of 80 adults with diabetic NeP in Dunedin, Otago region, New Zealand, from November 2013. Outcomes include two questionnaires: Pain OM – modified brief pain inventory (mBPI)-diabetic peripheral neuropathy item scale; and physical functional OM – screening of activity limitation and safety awareness (SALSA) scale. To capture the reliability and validity of these measures two follow-up assessments (4 and 12 weeks after the baseline assessment) will be scheduled. For test–retest reliability, ‘Intraclass Correlation Coefficient’ (ICC), and to find out the correlation between two measures, ‘Pearson correlation coefficient’ will be calculated. To investigate responsiveness, ‘Minimally Clinically Important Change’ (MCIC) scores will be calculated.

Ethics and Dissemination: Full final ethical approval from the University of Otago Human Ethics Committee has been obtained: Ethical Committee reference number H13/041. Maori Research Consultation through the Ngai Tahu Research Committee has also been undertaken. Trial registration: The Australian New Zealand Clinical Trials.

Keywords: Diabetic neuropathy, Pain intensity outcome measure, Physical functioning outcome measure, Psychometric properties, Reliability, Validity, Responsiveness

Background
Diabetic neuropathic pain (NeP) is defined as ‘pain arising as a direct consequence of abnormalities in the peripheral somatosensory system in people with diabetes’ (International Association for the Study of Pain).1,2 Diabetic NeP is considered to be a multi-disabling condition, affecting 15% or more diabetic patients.3 For those with diabetic NeP, pain is considered a risk factor for, as well as a cause of disability.4 According to the International Classification of Functioning, Disability and Health, functioning is described as a complex interaction of body functions, body structures, activities and participation, and environmental and personal factors and has provided a theoretical framework for evaluating functioning and disability.5 In order to achieve the aims of complete rehabilitation, evaluation of pain along with subjective interaction of pain and comorbidities should be assessed.

A range of pain assessment guidelines have been developed including the Initiative on Methods, Measurement and Pain Assessment in Clinical Trials (IMMPACT)6 along with assessment guidelines from

Correspondence to: Poonam Mehta, Centre for Health, Activity, and Rehabilitation Research, 325 Great King Street, PO Box: 56, Dunedin 9054, New Zealand. Email: drpoonammeheta25@gmail.com

DOI 10.1179/1743288X14Y.0000000157

Physical Therapy Reviews 2014 VOL. 19 NO. 6
the European Federation of Neurological Sciences (EFNS)\textsuperscript{7,8} and the Neuropathic Pain Special Interest Group (NeuPSIG).\textsuperscript{9} These guidelines recommend outcome measures (OMs) that evaluate a range of issues associated with NeP, such as pain, quality of life, mood, sleep, and functional capacity (physical, cognitive, emotional, and social).\textsuperscript{8,9} As numerous other OMs are also available, justification for selection for clinical practice or clinical trials must be based on the extent of established psychometric properties (PMP).

The various domains of PMPs include reliability, validity, and dimensionality. Reliability is a measure of stability, consistency, and homogeneity; whereas validity involves multiple forms of measures that include content, construct, criterion, and face validity. Responsiveness is considered a validity measure and involves the accurate reflection of change within the tool when a clinically meaningful change has occurred within the respondent. Related to responsiveness is interpretability, which is the interpretation of the extent of change necessary for clinical importance.

Dimensionality is a PMP that involves the assessment of one or more specific latent constructs.\textsuperscript{10} The Brief Pain Inventory (BPI) is a widely used and validated numeric rating scale that measures severity of pain and its interference with daily functions.\textsuperscript{11} The modified form of BPI, modified Brief Pain Inventory for Diabetic Peripheral Neuropathy (mBPI-DPN), is a patient-completed numeric rating scale specifically designed for diabetic peripheral neuropathy, which includes a four item pain severity scale and a seven item pain interference scale. Initially, formal validation of BPI in NeP was not conducted, though it was used widely in clinical trials of NeP.\textsuperscript{12} The initial validation of this tool was done in a herpes zoster population,\textsuperscript{13} followed by the establishment of other PMPs.\textsuperscript{14} Due to fluctuations of NeP over time, mBPI-DPN scales assessing average pain by measuring the ‘pain at its worst’, ‘pain at its least’, and ‘pain right now’ have been recommended to assess pain and disability in patients with diabetic neuropathy. Both scales of the mBPI-DPN OM (pain severity scale and pain interference scale) have been established for their internal consistency (high Cronbach’s alpha $\alpha=0.90$ and criterion validity) as the mean pain severity scale was highly correlated with bodily pain from the medical outcome study short form-12 version 2 (Spearman correlation coefficient $r=0.63$, $P<0.001$), the pain/discomfort item in the Euro-QoL (Spearman correlation coefficient $r=0.58$, $P<0.001$), and a verbal rating scale measure of pain severity (Spearman correlation coefficient $r=0.74$, $P<0.001$).\textsuperscript{14} Individual mBPI-DPN interference domains have been found to moderately correlate (Spearman correlation coefficient $r>0.5$, $P<0.001$) with analogous measures, and the Sleep Interference item had a high, significant association with the three primary Medical Outcome Study-Sleep Scale subscales (Spearman correlation coefficient $r>0.66–71$, $P<0.001$).\textsuperscript{15,16}

However, no further published evidence for the other forms of PMPs, i.e. test–retest reliability and responsiveness/interpretability form of validity has been found. To make the further recommendations for the future use of this measure, there is a need to establish these remaining PMPs in the underlying population.

The original Screening of Activity Limitation and Safety Awareness (SALSA) scale is a 374-item questionnaire, comprising 19 different sections of self-care, around the house, reading and writing, getting around, leisure, child care, working with tools, etc. Twenty items from this original 374-item questionnaire were selected and approved by the SALSA collaborative study group to be applied in diabetic NeP and leprosy populations.\textsuperscript{17} This tool has been shown to discriminate between people with and without activity limitation in these populations. The short form SALSA questionnaire has been established for its high reliability coefficient (Cronbach’s alpha $\alpha=0.884$) and a strong association found between the SALSA score and the score assigned to the respondents by the independent experts (Spearman correlation coefficient $r=0.70$, $P<0.0001$); thus this scale has been found to be sensitive to the changes in the diabetic neuropathic population. However, the validation of this scale should be considered as preliminary, as its sensitivity to change has not been assessed to date in further clinical trials. The test–retest reliability of short form SALSA has been determined only in a leprosy population.\textsuperscript{18} Additionally, no published evidence for the other forms of PMPs, i.e. test–retest reliability in diabetic NeP population, and responsiveness/interpretability form of validity, has been found. Since, for clinical and research purposes, it is imperative that PMPs are established for these OMs, the proposed research aims to investigate the test–retest reliability, responsiveness, and interpretability (minimally clinically important change – MCIC) of pain intensity (mBPI-DPN) and physical functioning (SALSA) OMs in adults with chronic diabetic NeP. Psychometrically sound instruments are essential to assist healthcare professionals to accurately measure and monitor changes in patient health, to assess the efficacy of interventions and to facilitate goal settings for therapeutic interventions. As the severity of pain and its impact on daily life (including disability) should also be explored, the study further aims to assess the relationship between these two measures.

**Methods**

**Study design**

This prospective longitudinal cohort study aims to recruit diabetic participants with nerve pain, from New Zealand, initiating in March 2014.
Sample size estimation

We are aiming to recruit n=80 adults for the study. Following Donner and Eliasziw’s equation[^19] for the calculation of sample size, considering two possible observations per subject and level of significance (α=0.05, a type II error; β=0.20, ρ₀=0.5, ρ₁=0.7), sample size for the reliability study was estimated to be 63 participants[^20,21] (null hypothesis = ρ₀=minimal acceptable level of reliability, and alternate hypothesis =ρ₁>p₀). N=80 sample size was decided after considering the 10–15% attrition rate because of withdrawal and discontinuity of participants during the study. Furthermore, the current sample size is also in recommendations of the Consensus-based Standards for the selection of Health Measurement Instruments (COSMIN)^[^22] checklist, developed by an international group of experts. According to COSMIN guidelines[^23] a sample size between 50 and 99 is considered to be a good sample size as they recognize the need for precision in the overall estimates.

Participant recruitment

For recruitment, advertisement flyers/posters will be circulated to health care centres, physiotherapy clinics, and university premises. Other sources of advertisements such as public media (e.g. local newspapers), public notice boards (e.g. public library and community local boards), university newsletter, and social networking sites (FaceBook invitations to Diabetes New Zealand; Peripheral Neuropathy New Zealand, etc.) will also be considered. Invitation letters to General Physicians and Diabetes NZ branches will also be posted requesting them to refer potential patients to participate in the study. A snowball sampling technique (exponential non-discriminative) as a chain referral will be followed[^24] Under such a methodology, participants who enter into the study will be asked to provide assistance to help identify additional people with similar characteristics.

Adults with a history of diabetes and chronic pain, who are interested in volunteering for the study, will be requested to contact the research administrator (telephonically or by electronic mail) at the Centre for Health, Activity, and Rehabilitation Research (CHARR), University of Otago. The research team will contact volunteers (telephonically) and screen for eligibility using a standardized procedure. Participants will be asked a set of questions from the Leeds Assessment of Neuropathic Symptoms and Signs: self-complete questionnaire (S-LANSS) in a telephonic interview by the primary investigator (PI). Participants scoring ≥12 on the S-LANSS, which has been suggestive of pain of predominantly nerve origin[^25] will be eligible to participate in the study. Eligible participants will then be provided with their first appointment with the PI at the CHARR. After obtaining written informed consent, a unique identification code will be assigned to each participant. Figure 1 summarizes the procedure to be adopted.

Selection criteria

Inclusion criteria: Adults (18 years and over) with a confirmed diagnosis of diabetes by a general physician, associated with chronic (defined as pain duration for ≥3 months[^26] NeP and a score of ≥12 on the S-LANNS will be eligible to participate. Participants should be able to understand English and provide informed consent to participate. Exclusion criteria: Participants who are unable to comprehend and record OM data will be excluded.

Measurements

Data will be collected at baseline, then at week 4 and week 12. After patients sign an informed consent document, they will be asked to answer a baseline questionnaire, stating their demographic details, various historical (diabetic, drug, etc.) questions followed by the physical measurements (height, weight, waist circumference, and hip circumference). The Charlson Comorbidity Index will be used to assess the presence of other associated illnesses in included participants[^27–29] The New Zealand Physical Activity Questionnaire: Short Form – Version 1 will also be incorporated to assess the level of physical activity of the participants[^30] Followed by demographic information, each participant will be requested to complete two questionnaires: the mBPI-DPN item scale and the short form SALSA scale. The Patient Global Impression of Change (PGiC) scale will be used as an external criterion at the follow-up visits.

The modified brief pain inventory – diabetic peripheral neuropathy item scale

The mBPI-DPN: pain severity scale and pain interference scale, is a patient-completed numeric rating scale. Each BPI item uses a 0–10 rating anchored at 0 for ‘no pain’ and 10 for ‘pain as bad as you can imagine’ for severity, and a 0–10 scale to measure interference from 0 ‘does not interfere’ to 10 ‘completely interferes’. The participants will be asked to report the level of pain experienced at different occasions. To distinguish between pain due to diabetic peripheral neuropathy and pain due to other causes, the following phrase is added to all items ‘due to your diabetes’ (as already used in the prior study[^14]).

The short form screening of activity limitation and safety awareness scale

The short form SALSA is also a patient-completed physical functional scale. For the purpose of scoring, participants will be asked whether a particular activity was ever carried out by the respondent. If the response is NO, then the item is graded as zero. However, if the response is a YES, grading is provided by asking further questions, such as whether this was perceived
as easy: Grade 1, whether it was perceived as a little difficult: Grade 2, whether it was very difficult: Grade 3, and if patient indicates that this activity was physically impossible or avoided because of a perceived risk of injury: Grade 4, indicating advanced degree of activity limitation.

Figure 1 Flow diagram summarizing the participant recruitment and procedure followed.
The patient global impression of change scale
The PGIC is a patient-completed numeric rating scale. The participant will be instructed to write down their present chief complaint followed by the question: ‘Since beginning this study, how would you describe the change (if any) in activity limitations, symptoms, emotions, and overall Quality of Life, related to your painful condition?’. (adapted from previous study). To determine subjective perception of improvement.31 Based on previous studies, a score of 5–7 will be considered as a significant, favourable change and a 1–4 score will be considered as no significant change. For the sensitivity and specificity approach, receiver operating characteristic (ROC) curves at 95% CIs will be used to discriminate between ‘major improvement’ and ‘unimportant change’. The area under the ROC curve will be interpreted as the probability that scores have correctly identified the patients classified as having ‘major improvement’ to ‘unimportant change’ by the external criterion.15

To handle missing data, initially a ‘follow-up’ strategy will be adopted.33 Participants who either failed to report on second and/or third assessments, or failed to fill any section of the questionnaires, will be contacted telephonically, or via e-mail to obtain their readings. However, if this strategy is not feasible, then the ‘Last observation carried forward’ method will be preferred.33 Here, the participant’s last data point before dropping out or at prior assessment will be used as the OM.

Validity
The MCIC scores for mBPI-DPN and SALSA scale will be calculated using three different variations of the ‘Anchor based approach’: ‘sensitivity and specificity’ approach, ‘within patients’ score change, and ‘between patients’ score change. The PGIC will be used as an external criterion based on the patient’s subjective perception of improvement.31 Based on previous studies, a score of 5–7 will be considered as a significant, favourable change and a 1–4 score will be considered as no significant change. For the sensitivity and specificity approach, receiver operating characteristic (ROC) curves at 95% CIs will be used to discriminate between ‘major improvement’ and ‘unimportant change’. The area under the ROC curve will be interpreted as the probability that scores have correctly identified the patients classified as having ‘major improvement’ to ‘unimportant change’ by the external criterion.15 The ‘within patients’ change will be calculated as the mean change score (Assessment 3 minus Assessment 1) for mBPI-DPN and SALSA, corresponding to the patients defined as achieving significant favourable change (score of 5–7 on PGIC). The ‘between patients’ change score will be calculated as the difference in the
change score of ‘significant favourable change’ (a score of 5–7 on PGIC) and ‘no significant change’ (a score of 1–4 on PGIC).\textsuperscript{15}

Correlation
The ‘Pearson correlation coefficient’ will be used to investigate the correlation between pain (mBPI-DPN) and physical functional (SALSA) OMs.\textsuperscript{37} A coefficient of +1 indicates that the variables (pain and physical functioning) are perfectly positively correlated, and thus as the scores for pain intensity increase, the physical functional limitation also increases commensurately. The ‘scatter plot method’ will be used to illustrate these findings; this will provide information about the variables: whether there is any relationship between the two variables? What kind of relationship it is, negative or positive? And whether any cases are markedly different from the others? The following criteria will be used to assess the strength of associations: 0.00–0.25 little or no correlation; 0.25–0.50 fair relationship; 0.50–0.75 moderate to good relationship; and above 0.75 good to excellent relationship.\textsuperscript{15}

Ethics and Dissemination
Ethical approval from the University of Otago Human Ethics Committee has been obtained for this study: Ethical Committee reference number H13/041. Maori Research Consultation through the Ngai Tahu Research Committee has also been undertaken. This trial has been registered with the Australian New Zealand Clinical Trials Registry: ACTRN12613000748718; the Universal Trial Number (UTN): U11111-1145-2867.

There are no potential risks for participants taking part in this study. All the participants will provide written informed consent to participate and will have all the rights to withdraw from participation in the project at any time without any disadvantage to them of any kind. This study will establish benchmark OMs that are originally constructed to measure pain and physical functioning status in individuals with diabetic NeP. This research will investigate whether relationships exist between pain perception and physical activity threshold in a diabetic NeP population. Furthermore, the results will add to our knowledge of what amount of change in pain intensity or physical functioning level might be considered as beneficial for the diabetic NeP participants. This will also be useful for clinicians and researchers to evaluate a change in pain and physical functioning status in individuals with diabetic NeP following interventions, thus better informing appropriate management to minimize the risks of comorbidities and disabilities.

Trial Status
At the time of submission of this study protocol, we are recruiting participants for the study.

Abbreviations
mBPI-DPN, the modified brief pain inventory-diabetic peripheral neuropathy item scale; CIs, confidence intervals; COSMIN, the COnsensus based Standards for the selection of health status Measurement INstruments guidelines; EFNS, the European Federation of Neurological Sciences; IASP, The International Association for the Study of Pain; ICC, intraclass correlation coefficient; IMMPACT, the initiative on methods, measurement and pain assessment in clinical trials; MCIC, minimally clinically important change; NeuPSIG, The Neuropathic Pain Special Interest Group; OMs, outcome measures; PGIC, the patient global impression of change scale; PI, primary investigator; RCTs, randomized controlled trials; ROC, receiver operating characteristic; SALSA, the screening of activity limitation and safety awareness scale; SEM, standard errors of measurement; S-LANSS, The Leeds Assessment of Neuropathic Symptoms and Signs: self-complete questionnaire; WHO, The World Health Organization.

Disclaimer Statements
Contributors PM drafted the manuscript. LC, RM, PH, and GDB critically revised the manuscript. All authors have been involved in the design of the study. All authors have read and approved the final manuscript.

Funding This project is supported by Centre for Health, Activity, and Rehabilitation Research, University of Otago, Dunedin, New Zealand, internal grant and the Mark Steptoe Memorial Trust, School of Physiotherapy; University of Otago, Dunedin, New Zealand.

Conflicts of interest All authors declare that there exist no conflicts of financial or non-financial competing interests associated with the current study.

Ethics approval Information is available under the section ‘Ethics and Dissemination’.

Acknowledgements
The authors thank and acknowledge Prof Chad Cook, for his suggestions, invaluable constant assistance, and helping with constructive feedback on drafts of the manuscript. We would like to express our gratitude to Centre for Health Activity and Rehabilitation Research, School of Physiotherapy, University of Otago, New Zealand departmental funds to partly support this study. We would also like to acknowledge the Mark Steptoe Memorial Trust, School of Physiotherapy, University of Otago, New Zealand, for providing the rest of financial assistance.
References

1. Treede RD. Redefinition of neuropathic pain and a grading system for clinical use: consensus statement on clinical and research diagnostic criteria. Neurology. 2008;70(18):1630.

2. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempfner P, Gribble C. Neuropathic pain: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diab Care. 2010;33(10):2285–93.

3. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002;18(6):350–4.

4. Von Korff M, Katon W, Lin EH, Simon G, Ciechanowski P, Ludman E, et al. Work disability among adults with diabetes. Diab Care. 2005;28(6):1326–32.

5. Stucki G, Cieza A, Ewert T, Kostanjsek N, Chatterji S, Ustun B. Quality criteria were proposed for measuring, disability and health (ICF) in clinical practice. Disabil Rehabil. 2002;24(5):281–2.

6. Dworkin RH, Backonja M, Rowbotham MC, Allen RR, Argoff CR, Bennett GJ, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003;60(11):1524–34.

7. Cruccu G, Anand P, Attal N, Garcia-Larrea L, Haanpaa M, Jorom E, et al. EFNS guidelines on neuropathic pain assessment. Eur J Neurol. 2004;11(3):153–62.

8. Cruccu G, Sommer C, Anand P, Attal N, Baron R, Garcia-Larrea L, et al. EFNS guidelines on neuropathic pain assessment: revised 2009. Eur J Neurol. 2010;17(8):1010–8.

9. Haanpaa M, Attal N, Backonja M, Baron R, Bennett M, Bouhassira D, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain. 2011;152(1):14–27.

10. Nunnally JC, Bernstein IH. Psychometric theory, 3rd edn. New York: McGraw-Hill; 1994. p. 736.

11. Cleeland CS, Ryan KM. Pain assessment: global use of the brief pain inventory. Ann Acad Med. 1994;23(2):129–38.

12. Gilron I, Booher SL, Rowan MS, Smoller MS, Max MB. A randomized, controlled trial of high-dose dextromethorphan in facial neuralgias. Neurology. 2000;55(7):964–8.

13. Sullivan M. Measuring functioning and well-being – the medical outcomes study approach. In: Stewart AL, Ware JE, editors. Psycho-oncology; Duke University Press; 1995, vol. 4(2). p. 163–5.

14. Zelman DC, Gore M, Dukes E, Tai KS, Brandenburg N. Validation of a modified version of the brief pain inventory for painful diabetic peripheral neuropathy. J Pain Symptom Manage. 2005;29(4):401–10.

15. Portney LG, Watkins MP. Foundations of clinical research. applications to practice, 3rd revised United States edn. Upper Saddle River/US: Prentice Hall; 2007.

16. Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007;60(1):34–42.

17. Group SCS, Ebenso J, Fuzikawa P, Melchior H, Wexler R, Piefer A, et al. The development of a short questionnaire for screening of activity limitation and safety awareness (SALSA) in clients affected by leprosy or diabetes. Disabil Rehabil. 2007;29(9):689–700.

18. Ebenso J, Velena JP. Test-retest reliability of the Screening Activity Limitation and Safety Awareness (SALSA) scale in North-West Nigeria. Leprosy Rev. 2009;80(2):197–204.

19. Donner A, Eliaziw M. Sample size requirements for reliability studies. Stat Med. 1987;6(4):441–8.

20. Walter SD, Eliaziw M, Donner A. Sample size and optimal designs for reliability studies. Stat Med. 1998;17(1):101–10.

21. Sim J, Wright CC. The kappa statistic in reliability studies: use, interpretation, and sample size requirements. Phys Ther. 2005;85(3):257–68.

22. Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, et al. The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. J Clin Epidemiol. 2010;63(7):737–45.

23. Merkies IS, Schmitz PI, van der Meche FG, van Doorn PA. Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology. 2000;54(4):943–9.

24. Biernacki P, Waldorf D. Snowball sampling: problems and techniques of chain referral sampling. Sociol Methods Res. 1981;10(2):141–63.

25. Bennett MI, Smith BH, Torrance N, Potter J. The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. J Pain. 2005;6(3):149–58.

26. Merskey H, Bogduk N. Classification of chronic pain, part III: pain terms, a current list with definitions and notes on usage, 2nd edn. Seattle: IASP Press; 2011.

27. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol. 2003;56(3):221–9.

28. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.

29. McLean G, Tobias M. The New Zealand physical activity questionnaires: Report on the validation and use of the NZPAQ-LF and NZPAQ-SF self-report physical activity survey instruments. New Zealand: SPARC; 2004.

30. Hurst H, Bolton J. Assessing the clinical significance of change scores recorded on subjective outcome measures. J Manipulative Physiol Ther. 2004;27(1):26–35.

31. Dillman DA. Mail and internet surveys: the tailored design method. New York: Wiley; 2000.

32. Streiner D, Geddes J. Intention to treat analysis in clinical trials when there are missing data. Evid Based Ment Health. 2001;4(3):70–1.

33. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86(2):420–8.

34. Lexell JE, Downham DY. How to assess the reliability of measurements in rehabilitation. Am J Phys Med Rehabil. 2005;84(9):719–23.

35. Schmitz-Hubsch T, Fimmers R, Rakowicz M, Rola R, Zdzienicka E, Fancellu R, et al. Responsiveness of different rating instruments in spinocerebellar ataxia patients. Neurology. 2010;74(6):678–84.

36. Field A. Discovering statistics using IBM SPSS statistics, Fourth (January 24, 2013) edn. London: SAGE Publications Ltd; 2013.